Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Launched by INVIRSA, INC. · Nov 23, 2022
Trial Information
Current as of January 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female patient ≥ 18 years of age
- • A clinical diagnosis of AIK with a minimum of a 2+ (moderate) conjunctival hyperemia and a minimum of 1+ (mild) discharge (whether it be watery or purulent) in at least one eye
- Exclusion Criteria:
- • Untreated keratoconjunctivitis of any type that has lasted 96 consecutive hours or more prior to baseline visit
- • Infectious blepharitis as the primary cause of ocular hyperemia and discharge in the opinion of the investigator (Note: If the blepharitis is secondary to the conjunctivitis, the patient can be included)
- • Suspected allergic conjunctivitis as a primary cause of conjunctival hyperemia (bulbar redness) and/or discharge in the opinion of the Investigator
- • Suspected corneal ulcer
- • Ocular topical steroid use within two weeks prior to baseline visit
- • Ocular topical antibiotic use for less than 24 hours or greater than 96 hours of dosing prior to Baseline visit (this does NOT exclude naïve patients or patients that have not taken topical antibiotics)
- • Ocular topical povidone iodine use within 1 week prior to baseline visit
- • Systemic antibiotic use within 2 weeks prior to baseline visit
- • Ocular topical or systemic anti-fungal within 2 weeks prior to baseline visit
- • Ocular topical or systemic anti-viral use within 2 weeks prior to baseline visit
- • Corticosteroid (including but not limited to oral, intranasal, inhaled, topical, etc.) or any immunosuppressant use within 30 days prior to Baseline visit
- • On current treatment for herpes keratitis (evidence of herpes keratitis and/or ocular dendrites can be included)
- • Known or suspected ocular fungal infection or ocular microsporidia infection
About Invirsa, Inc.
Invirsa, Inc. is a biopharmaceutical company dedicated to advancing innovative therapies for the prevention and treatment of viral infections and related diseases. With a focus on harnessing cutting-edge technologies, Invirsa is committed to developing novel antiviral solutions that address unmet medical needs. The company’s research initiatives are guided by a robust scientific foundation and a strong emphasis on clinical efficacy and safety. Through strategic partnerships and collaborations, Invirsa aims to bring transformative therapies to market, improving patient outcomes and enhancing public health globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Bangkok, , Thailand
Bangkok, , Thailand
Glendale, California, United States
Miami, Florida, United States
Pasadena, California, United States
Largo, Florida, United States
Athens, Ohio, United States
Miami Beach, Florida, United States
Miami, Florida, United States
Bangkok, , Thailand
Bangkok, , Thailand
Pittsburg, Kansas, United States
Garner, North Carolina, United States
Lakeway, Texas, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials